Jeffrey Masten

Senior Vice President CMC at Secretome Therapeutics

Speaker

Mr. Masten is currently serving Secretome Therapeutics developing all aspects of CMC activities for their neonatal MSC’s and their Secretome product in clinical trials. Most recently he served as Chief Operating Officer at Theragent Inc's CDMO operations since inception in 2021 where he was responsible for the design/build/qualification and start-up of their paperless GMP facility and operations. Previously, Jeff was serving JUNO Therapeutics/Bristol Myers Squibb as the Vice President, Quality responsible for GMP site readiness for Breyanzi’s BLA submission and eventual commercial approval to treat patients with Large B-cell Lymphoma. Prior to his time at JUNO, Jeff was responsible for all aspects of CMC development for multiple cell therapy programs for Atara Bio. Prior positions to Atara include senior executive level positions at Aventis Behring and Genentech where he was responsible for commercial approval of 5 PAI and design build of over 500K Sq.Ft. of commercial manufacturing space. Jeff earned his graduate MBA degree at the University of Notre Dame and undergraduate work at Salisbury University and Indiana University in Chemistry and Business Administration.